September 26, 2020
Video
The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.
September 23, 2020
Video
The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.
September 22, 2020
Video
The director of the UCSF Weill Institute for Neuroscience offered his perspective on data presented at MS Virtual suggesting ofatumumab’s benefit in patients with MS who were treatment naïve.
Serum Neurofilament Light Poses as Critical Biomarker During Ataxic, Preataxic Stages of Spinocerebellar Ataxias
Connecting ALS: How New Drug Coverage Decisions Are Made
NeuroVoices: Mark Lew, MD, on the Validation of Tears as a Biomarker for Parkinson Disease
AlzoSure Predict Test Shows Predictive Ability for Alzheimer Disease Years Prior to Diagnosis